vs
Side-by-side financial comparison of Arbutus Biopharma Corp (ABUS) and Paranovus Entertainment Technology Ltd. (PAVS). Click either name above to swap in a different company.
Paranovus Entertainment Technology Ltd. is the larger business by last-quarter revenue ($12.4M vs $10.7M, roughly 1.2× Arbutus Biopharma Corp). Arbutus Biopharma Corp runs the higher net margin — 23.5% vs -5.5%, a 29.0% gap on every dollar of revenue. On growth, Paranovus Entertainment Technology Ltd. posted the faster year-over-year revenue change (18033.4% vs 522.2%).
Arbutus Biopharma Corporation is a publicly traded Canadian biopharmaceutical company with an expertise in liposomal drug delivery and RNA interference, and is developing drugs for hepatitis B infection.
ABUS vs PAVS — Head-to-Head
Income Statement — Q2 FY2025 vs Q2 FY2026
| Metric | | |
|---|---|---|
| Revenue | $10.7M | $12.4M |
| Net Profit | $2.5M | $-681.0K |
| Gross Margin | — | 20.0% |
| Operating Margin | 13.9% | -5.1% |
| Net Margin | 23.5% | -5.5% |
| Revenue YoY | 522.2% | 18033.4% |
| Net Profit YoY | 112.7% | 61.4% |
| EPS (diluted) | $0.01 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q3 25 | — | $12.4M | ||
| Q2 25 | $10.7M | — | ||
| Q4 23 | $2.1M | — | ||
| Q3 23 | $4.7M | $0 | ||
| Q2 23 | $4.7M | — | ||
| Q1 23 | $6.7M | — | ||
| Q4 22 | $6.2M | — | ||
| Q3 22 | $6.0M | — |
| Q3 25 | — | $-681.0K | ||
| Q2 25 | $2.5M | — | ||
| Q4 23 | — | — | ||
| Q3 23 | $-20.1M | $8.2M | ||
| Q2 23 | $-17.1M | — | ||
| Q1 23 | $-16.3M | — | ||
| Q4 22 | $-21.9M | — | ||
| Q3 22 | $-17.6M | — |
| Q3 25 | — | 20.0% | ||
| Q2 25 | — | — | ||
| Q4 23 | — | — | ||
| Q3 23 | — | — | ||
| Q2 23 | — | — | ||
| Q1 23 | — | — | ||
| Q4 22 | — | — | ||
| Q3 22 | — | — |
| Q3 25 | — | -5.1% | ||
| Q2 25 | 13.9% | — | ||
| Q4 23 | -967.2% | — | ||
| Q3 23 | -462.8% | — | ||
| Q2 23 | -395.3% | — | ||
| Q1 23 | -260.4% | — | ||
| Q4 22 | -361.3% | — | ||
| Q3 22 | -299.2% | — |
| Q3 25 | — | -5.5% | ||
| Q2 25 | 23.5% | — | ||
| Q4 23 | — | — | ||
| Q3 23 | -431.6% | — | ||
| Q2 23 | -367.5% | — | ||
| Q1 23 | -244.3% | — | ||
| Q4 22 | -351.2% | — | ||
| Q3 22 | -295.1% | — |
| Q3 25 | — | — | ||
| Q2 25 | $0.01 | — | ||
| Q4 23 | $-0.12 | — | ||
| Q3 23 | $-0.12 | — | ||
| Q2 23 | $-0.10 | — | ||
| Q1 23 | $-0.10 | — | ||
| Q4 22 | $-0.13 | — | ||
| Q3 22 | $-0.12 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $37.4M | $5.2M |
| Total DebtLower is stronger | $0 | — |
| Stockholders' EquityBook value | $83.0M | $23.6M |
| Total Assets | $103.3M | $37.3M |
| Debt / EquityLower = less leverage | 0.00× | — |
8-quarter trend — quarters aligned by calendar period.
| Q3 25 | — | $5.2M | ||
| Q2 25 | $37.4M | — | ||
| Q4 23 | $126.0M | — | ||
| Q3 23 | $17.5M | $1.0M | ||
| Q2 23 | $27.2M | — | ||
| Q1 23 | $40.6M | — | ||
| Q4 22 | $146.9M | — | ||
| Q3 22 | $24.0M | — |
| Q3 25 | — | — | ||
| Q2 25 | $0 | — | ||
| Q4 23 | $0 | — | ||
| Q3 23 | $0 | — | ||
| Q2 23 | $0 | — | ||
| Q1 23 | $0 | — | ||
| Q4 22 | $0 | — | ||
| Q3 22 | $0 | — |
| Q3 25 | — | $23.6M | ||
| Q2 25 | $83.0M | — | ||
| Q4 23 | $106.0M | — | ||
| Q3 23 | $119.3M | $10.7M | ||
| Q2 23 | $134.7M | — | ||
| Q1 23 | $143.9M | — | ||
| Q4 22 | $136.9M | — | ||
| Q3 22 | $145.5M | — |
| Q3 25 | — | $37.3M | ||
| Q2 25 | $103.3M | — | ||
| Q4 23 | $144.4M | — | ||
| Q3 23 | $158.6M | $11.2M | ||
| Q2 23 | $176.8M | — | ||
| Q1 23 | $191.2M | — | ||
| Q4 22 | $195.4M | — | ||
| Q3 22 | $203.8M | — |
| Q3 25 | — | — | ||
| Q2 25 | 0.00× | — | ||
| Q4 23 | 0.00× | — | ||
| Q3 23 | 0.00× | — | ||
| Q2 23 | 0.00× | — | ||
| Q1 23 | 0.00× | — | ||
| Q4 22 | 0.00× | — | ||
| Q3 22 | 0.00× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-15.7M | $-159.3K |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | 0.0% | — |
| Cash ConversionOCF / Net Profit | -6.24× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q3 25 | — | $-159.3K | ||
| Q2 25 | $-15.7M | — | ||
| Q4 23 | $-17.3M | — | ||
| Q3 23 | $-21.8M | $-13.1M | ||
| Q2 23 | $-19.6M | — | ||
| Q1 23 | $-27.3M | — | ||
| Q4 22 | $-17.0M | — | ||
| Q3 22 | $-18.7M | — |
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q4 23 | — | — | ||
| Q3 23 | $-21.8M | — | ||
| Q2 23 | $-20.4M | — | ||
| Q1 23 | $-27.4M | — | ||
| Q4 22 | $-17.1M | — | ||
| Q3 22 | $-18.8M | — |
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q4 23 | — | — | ||
| Q3 23 | -468.4% | — | ||
| Q2 23 | -439.0% | — | ||
| Q1 23 | -410.0% | — | ||
| Q4 22 | -274.2% | — | ||
| Q3 22 | -315.6% | — |
| Q3 25 | — | — | ||
| Q2 25 | 0.0% | — | ||
| Q4 23 | 0.0% | — | ||
| Q3 23 | 0.7% | — | ||
| Q2 23 | 18.5% | — | ||
| Q1 23 | 1.7% | — | ||
| Q4 22 | 2.1% | — | ||
| Q3 22 | 1.5% | — |
| Q3 25 | — | — | ||
| Q2 25 | -6.24× | — | ||
| Q4 23 | — | — | ||
| Q3 23 | — | -1.60× | ||
| Q2 23 | — | — | ||
| Q1 23 | — | — | ||
| Q4 22 | — | — | ||
| Q3 22 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
